GLUT1 expression in human breast carcinoma

Correlation with known prognostic markers

M. Younes, R. W. Brown, D. R. Mody, L. Fernandez, Rodolfo Laucirica

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Background: Breast cancers have been shown to have increased glucose uptake and utilization, and to express the facilitative glucose transporter Glut1. The aim of this study was to determine the biological significance of Glut1 expression in breast cancer. Methods: Paraffin sections of 118 breast cancers were immunostained with antibody to Glut1. The percent of Glut1-positive cancer cells in each tumor was correlated with known prognostic markers, and with patient outcome. Results: Glut1 was expressed in 42% of the tumors. Glut1 immunoreactivity correlated positively with the proliferative activity as determined by Ki-67 immunostaining, and with the total histologic score, and showed negative correlation with bcl-2 immun immunostaining. There was no correlation between the percent of Glut1-immunoreactive cancer cells and estrogen receptor status, tumor size, or lymph node status. Conclusions: 1) Glut1 expression is increased in breast cancers with higher grade and proliferative activity, and 2) glucose transport in the majority of breast cancers may be mediated by a glucose transporters other than Glut1.

Original languageEnglish (US)
Pages (from-to)2895-2898
Number of pages4
JournalAnticancer Research
Volume15
Issue number6 B
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

Breast Neoplasms
Facilitative Glucose Transport Proteins
Neoplasms
Glucose
Estrogen Receptors
Paraffin
Lymph Nodes
Antibodies

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Younes, M., Brown, R. W., Mody, D. R., Fernandez, L., & Laucirica, R. (1995). GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers. Anticancer Research, 15(6 B), 2895-2898.

GLUT1 expression in human breast carcinoma : Correlation with known prognostic markers. / Younes, M.; Brown, R. W.; Mody, D. R.; Fernandez, L.; Laucirica, Rodolfo.

In: Anticancer Research, Vol. 15, No. 6 B, 01.12.1995, p. 2895-2898.

Research output: Contribution to journalArticle

Younes, M, Brown, RW, Mody, DR, Fernandez, L & Laucirica, R 1995, 'GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers', Anticancer Research, vol. 15, no. 6 B, pp. 2895-2898.
Younes, M. ; Brown, R. W. ; Mody, D. R. ; Fernandez, L. ; Laucirica, Rodolfo. / GLUT1 expression in human breast carcinoma : Correlation with known prognostic markers. In: Anticancer Research. 1995 ; Vol. 15, No. 6 B. pp. 2895-2898.
@article{414bfe5dd71e41fa8f9a1e1e1bba67e0,
title = "GLUT1 expression in human breast carcinoma: Correlation with known prognostic markers",
abstract = "Background: Breast cancers have been shown to have increased glucose uptake and utilization, and to express the facilitative glucose transporter Glut1. The aim of this study was to determine the biological significance of Glut1 expression in breast cancer. Methods: Paraffin sections of 118 breast cancers were immunostained with antibody to Glut1. The percent of Glut1-positive cancer cells in each tumor was correlated with known prognostic markers, and with patient outcome. Results: Glut1 was expressed in 42{\%} of the tumors. Glut1 immunoreactivity correlated positively with the proliferative activity as determined by Ki-67 immunostaining, and with the total histologic score, and showed negative correlation with bcl-2 immun immunostaining. There was no correlation between the percent of Glut1-immunoreactive cancer cells and estrogen receptor status, tumor size, or lymph node status. Conclusions: 1) Glut1 expression is increased in breast cancers with higher grade and proliferative activity, and 2) glucose transport in the majority of breast cancers may be mediated by a glucose transporters other than Glut1.",
author = "M. Younes and Brown, {R. W.} and Mody, {D. R.} and L. Fernandez and Rodolfo Laucirica",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "15",
pages = "2895--2898",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - GLUT1 expression in human breast carcinoma

T2 - Correlation with known prognostic markers

AU - Younes, M.

AU - Brown, R. W.

AU - Mody, D. R.

AU - Fernandez, L.

AU - Laucirica, Rodolfo

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Background: Breast cancers have been shown to have increased glucose uptake and utilization, and to express the facilitative glucose transporter Glut1. The aim of this study was to determine the biological significance of Glut1 expression in breast cancer. Methods: Paraffin sections of 118 breast cancers were immunostained with antibody to Glut1. The percent of Glut1-positive cancer cells in each tumor was correlated with known prognostic markers, and with patient outcome. Results: Glut1 was expressed in 42% of the tumors. Glut1 immunoreactivity correlated positively with the proliferative activity as determined by Ki-67 immunostaining, and with the total histologic score, and showed negative correlation with bcl-2 immun immunostaining. There was no correlation between the percent of Glut1-immunoreactive cancer cells and estrogen receptor status, tumor size, or lymph node status. Conclusions: 1) Glut1 expression is increased in breast cancers with higher grade and proliferative activity, and 2) glucose transport in the majority of breast cancers may be mediated by a glucose transporters other than Glut1.

AB - Background: Breast cancers have been shown to have increased glucose uptake and utilization, and to express the facilitative glucose transporter Glut1. The aim of this study was to determine the biological significance of Glut1 expression in breast cancer. Methods: Paraffin sections of 118 breast cancers were immunostained with antibody to Glut1. The percent of Glut1-positive cancer cells in each tumor was correlated with known prognostic markers, and with patient outcome. Results: Glut1 was expressed in 42% of the tumors. Glut1 immunoreactivity correlated positively with the proliferative activity as determined by Ki-67 immunostaining, and with the total histologic score, and showed negative correlation with bcl-2 immun immunostaining. There was no correlation between the percent of Glut1-immunoreactive cancer cells and estrogen receptor status, tumor size, or lymph node status. Conclusions: 1) Glut1 expression is increased in breast cancers with higher grade and proliferative activity, and 2) glucose transport in the majority of breast cancers may be mediated by a glucose transporters other than Glut1.

UR - http://www.scopus.com/inward/record.url?scp=0029554059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029554059&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 2895

EP - 2898

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -